1Department of Emergency Medicine, I. I. Mechnikov North-Western State Medical University, Ministry of Health of the Russian Federation, St.
Petersburg, Russia
2Department of Neurology, Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation, St. Petersburg,
Russia
Asthenia commonly coexists with cognitive impairment, anxiety, depressive symptoms, and sleep disturbances. Serotonergic systems modulate cholinergic activity, providing a rationale for investigating choline and Ginkgo biloba supplementation. This study evaluated changes in asthenic symptoms, cognition, and associated manifestations during supplementation. A prospective, open- label study included 44 adults aged 45-65 years, including 20 healthy controls; patients had asthenia and mild to moderate cognitive impairment. Choline Strong, containing choline 550 mg and standardized Ginkgo biloba 60 mg per capsule, was administered as one capsule twice daily for 60 days. Assessments were performed at baseline and on Days 30 and 60 using the Asthenic State Scale, Multidimensional Fatigue Inventory (MFI-20), Montreal Cognitive Assessment (MoCA), Schulte tables test, Spielberger anxiety inventory, Beck Depression Inventory, and sleep quality questionnaire. Changes across cognitive, emotional, and fatigue-related domains were evaluated to characterize the pattern and time course of clinical responses. Healthy controls provided reference values. Results were expressed as mean ± standard error. By Day 60, Asthenic State Scale scores decreased from 90.3 ± 5.2 to 55.2 ± 0.8, while MoCA scores increased from 25.4 ± 0.5 to 29.2 ± 0.1 (both p ≤ 0.01 versus baseline). Schulte test completion time decreased from 181.3 ± 8.2 to 50.9 ± 5.6 seconds (p ≤ 0.01). State anxiety scores decreased from 59.3 ± 2.0 to 30.2 ± 1.7, and depression scores decreased from 15.3 ± 0.8 to 9.7 ± 0.8. Sleep quality scores increased from 16.7 ± 1.2 to 20.8 ± 0.6. General, physical, and mental fatigue also improved, with changes evident by Day 30. No adverse events or treatment discontinuations were reported. Supplementation was associated with improvements in asthenia, cognition, and associated symptoms over 60 days. The open-label design and absence of a defined placebo comparator limit causal interpretation. Randomized, placebo-controlled studies are needed to confirm these findings.
Keywords: Asthenia; Cognitive Dysfunction; Depression; Choline Strong; Choline; Ginkgo biloba; Receptors; Asthenia Assessment Scales
Vasily V Afanasiev., et al. “Choline and Ginkgo biloba Supplementation in Adults with Asthenia and Cognitive Impairment: A Pro- spective Open-Label Study”. EC Neurology 18.11 (2026): 01-14.
© 2026 Vasily V Afanasiev., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Open Access by ECronicon is
licensed under a Creative Commons Attribution
4.0 International License
Based on a work at www.ecronicon.net